31/08/2026
Your experience matters. Have your say today!
If you live with pulmonary fibrosis or scleroderma-associated interstitial lung disease (SSc-ILD), you have an opportunity to share your lived experience as part of an important Pharmaceutical Benefits Advisory Committee (PBAC) consultation.
The PBAC is considering a potential new treatment option for pulmonary fibrosis and is seeking input from people affected by the condition to better understand its impact on daily life, wellbeing, independence and treatment needs.
Your lived experience can help decision-makers understand the real-world impact of these conditions.
There are several ways you can contribute, including using Patient Input Buddy, an AI-assisted online platform that can help you prepare your submission by guiding you through questions about your experience and helping you draft your response in your own words.
You can also submit your input directly to the PBAC or contribute to Scleroderma Australia’s submission.
👉 Visit www.patientinput.com.au to learn more and have your say.
Submissions close 16 September 2026.
Swipe through the carousel to learn more about the consultation and how you can participate.